Matter sensitive: HC seeks MD JKMSCL’s report on anti-haemophilic drugs
Srinagar, Oct 9: Observing the matter as “sensitive”, the High Court of J&K and Ladakh has asked the Managing Director (MD), Jammu and Kashmir Medical Supplies Corporation Limited (JKMSCL), to submit a detailed report regarding the non-availability of anti-haemophilic drugs in hospitals in Jammu and Kashmir.
In response to a related Public Interest Litigation, a division bench of Chief Justice Arun Palli and Justice Rajnesh Oswal observed that the matter is sensitive and has been pending for a while. “In the interregnum, numerous orders have been passed by this Court, which show that it requires immediate attention”
“Having heard learned counsel for the parties, we consider it expedient to request Managing Director, Jammu and Kashmir Medical Supplies Corporation Limited to take cognisance of the matter forthwith and submit a detailed report as regards the concerns/grievances that are sought to be made,” the court said and listed the matter for further consideration on October 14.
Filed in August this year, the PIL highlights the complete non-availability of the essential life-saving drugs like Factor VIII, Factor IX and Von Willebrand factor drugs, underlining that the patients in Jammu and Kashmir have to undergo a great deal of tribulations to get these drugs.
It seeks direction from the authorities to immediately ensure uninterrupted availability and supply of anti-haemophilic drugs and essential clotting factor concentrates to the Government Medical College, Srinagar and all other designated treatment centres across Jammu & Kashmir.
Moreover, the PIL seeks to release without any further delay, the entire quantity of anti-haemophilic drugs lying stocked with Jammu and Kashmir Medical Supplies Corporation Ltd to the concerned hospitals as per annual and supplementary requisitions raised by the concerned agencies.
